Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06683066 | Study on Human Bioequivalence of Triprerelin Acetate for Injection | recruiting | Phase 1 | 120 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06685562 | The 4D PICTURE Project: Evaluating Metro Mapping As a Method to Support Shared Decision Making in Oncology | recruiting | — | 500 | Leiden University Medical CenterOTHER | 3 | Nov 12, 2024 | clinicaltrials |
| NCT02899312 | PSMA PET/CT for Assessment of Recurrent Prostate Cancer | active not recruiting | — | 2,244 | British Columbia Cancer AgencyOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05001477 | Customized TULSA-PRO Ablation Registry(CARE) | recruiting | — | 1,000 | Profound Medical Inc.OTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT06579417 | ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer(ART-Pro) | recruiting | — | 500 | University of California, San DiegoOTHER | 2 | Nov 6, 2024 | clinicaltrials |
| NCT06662708 | Artificial Intelligence Models for Precision Prediction and Treatment of Prostate Cancer | not yet recruiting | N/A | 200 | Shao PengfeiOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06663007 | RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure | recruiting | Phase 1 / Phase 2 | 72 | Tianjin Medical University Second HospitalOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06584279 | Diagnostic Value of MRI-targeted Plus Index-lesion-ipsilaterally Systematic Biopsy for Biopsy-naive Men At Risk of Prostate Cancer | recruiting | — | 563 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT06617481 | PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence | recruiting | Phase 2 | 30 | AdventHealthOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT06655259 | Combination of TURP and Standard Systemic Therapy for MPCa(CTUSMEP01) | recruiting | Phase 2 | 200 | Fudan UniversityOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05558007 | Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients | recruiting | Phase 2 | 72 | Biozeus Biopharmaceutical S.A.INDUSTRY | 1 | Oct 22, 2024 | clinicaltrials |
| NCT06620016 | Circulating microRNAs in Small Testicular Masses and Retroperitoneal Post-chemotherapy Residual Masses.(SEARCH-1) | recruiting | — | 60 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT06636682 | FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer | recruiting | Phase 2 | 100 | Cellvax Therapeutics IncINDUSTRY | 1 | Oct 21, 2024 | clinicaltrials |
| NCT05629494 | Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test(ADAPT-PSA) | recruiting | Phase 4 | 198 | Albany Medical CollegeOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06274892 | Remote Monitoring of Patient Reported Outcomes to Improve the Efficacy of the Acute Phase Radiotherapy Review Process(PROMOTE) | recruiting | N/A | 124 | University Health Network, TorontoOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06636747 | High Resolution Diffusion Weighted Imaging in Prostate | recruiting | — | 500 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06637267 | Prospective Evaluation of Proclarix® Test to Improve Risk Stratification in Men Scheduled for MpMRI and Prostate Biopsy in Cantonal Hospital Aarau | recruiting | — | 480 | Kantonsspital AarauOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05129605 | Prostate Cancer Genetic Risk Evaluation and Screening Study(PROGRESS) | recruiting | — | 400 | Massachusetts General HospitalOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06634173 | The Diagnostic Value of FAPI PET/CT in Staging of Newly Diagnosed Prostate Cancer(proFAPI) | not yet recruiting | N/A | 30 | The Netherlands Cancer InstituteOTHER | 0 | Oct 9, 2024 | clinicaltrials |
| NCT06626386 | Determination of Prostate-specific Antigen in Capillary Blood (PSA-Cap)(PSA-Cap) | recruiting | — | 200 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT03230734 | Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer(RAPSON) | active not recruiting | Phase 2 | 70 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06071195 | All-in-One Prostate Cancer Staging with MRI(AllinOne_MRI) | recruiting | — | 400 | European Institute of OncologyOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614751 | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway | not yet recruiting | Phase 1 | 112 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06612580 | 68Ga-AAZTA-NI-093 PET/CT: First-in-human Study | recruiting | Early Phase 1 | 10 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT04571840 | Prostate Imaging Using MRI +/- Contrast Enhancement(PRIME) | active not recruiting | N/A | 500 | University College, LondonOTHER | 15 | Sep 23, 2024 | clinicaltrials |
| NCT05097820 | Prospective Observational Study on SEBBIN Silicone Gel-filled Testicular Implants | recruiting | — | 100 | University Hospital, GhentOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05100121 | To Live Better After Prostate Cancer Treatment:(CAPPRIS) | recruiting | N/A | 40 | Karolinska InstitutetOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05613023 | A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT(PACE-NODES) | recruiting | Phase 3 | 1,128 | Institute of Cancer Research, United KingdomOTHER | 3 | Sep 19, 2024 | clinicaltrials |
| NCT06184464 | Prostatic Size Reduction Following of Leuprorelin Acetate(PROSTSIZE) | recruiting | — | 40 | Consorci Sanitari de TerrassaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06521710 | Nerve Grafting Technique to Preserve Erectile Function in Patients Undergoing Robotic Assisted Radical Prostatectomy(NR-RALP) | recruiting | N/A | 10 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06585007 | Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer(MEDCARE) | recruiting | Phase 3 | 246 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT05361902 | A First Step Towards Ultra-hypofractionation for Unfavourable Intermediate and High-risk Prostate Cancer(UPRATE) | active not recruiting | N/A | 35 | Erasmus Medical CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06575257 | Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer | recruiting | Phase 2 | 80 | Xijing HospitalOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06279260 | National Robotics-Assisted Radical Prostatectomy Database(RASOR) | recruiting | — | 10,000 | Melbourne HealthOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06325774 | Radical Hypofractionated Radiotherapy for Localized Prostate Cancer | recruiting | N/A | 20 | Changhai HospitalOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06325995 | Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer | recruiting | N/A | 428 | Changhai HospitalOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT03360994 | WATChmAN Virtual Testicular Cancer Clinic | active not recruiting | N/A | 144 | University Health Network, TorontoOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06524219 | Comparison of Nerve-sparing Techniques in Radical Prostatectomy for Oncological Outcome and Functional Recovery. | not yet recruiting | — | 150 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 19, 2024 | clinicaltrials |
| NCT06362577 | Clinical Study of HIFU for Localized Prostate Cancer(HIFU) | recruiting | — | 60 | RenJi HospitalOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06343038 | Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study(PROGNOSTICS) | recruiting | Phase 1 | 25 | University Hospital, Basel, SwitzerlandOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06544720 | SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas | recruiting | Phase 1 | 18 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06546527 | Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC） | not yet recruiting | Early Phase 1 | 12 | Peking University First HospitalOTHER | 0 | Aug 9, 2024 | clinicaltrials |
| NCT06529549 | Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment | recruiting | — | 30 | Sun Yat-sen UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06518226 | Two-Fraction Ultrahypofractionated Radiotherapy With Focal Boost for Intermediate Risk, Localized Prostate Cancer(TURBO) | recruiting | N/A | 160 | UMC UtrechtOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT06494696 | 68Ga-PSMA PET/MRI in Conjunction With mpMRI for Evaluating Prospective Prostate Cancer Risk | recruiting | — | 71 | Chang Gung Memorial HospitalOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT06489496 | Prostate Cancer 18F-PSMA-1007 PET/CT Access Trial(PAX) | not yet recruiting | — | 1,000 | Alberta Health servicesOTHER | 0 | Jul 8, 2024 | clinicaltrials |
| NCT06491056 | Prospective Asian Multicenter Prostate Cancer Focal Therapy Study (ProAMFocal)(ProAMFocal) | recruiting | — | 500 | Singapore General HospitalOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT05549024 | 68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients | recruiting | Early Phase 1 | 90 | Peking Union Medical College HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 12, 2024source: clinicaltrials